Physician profile
Michael J Stephen
NPI 1275807638
$7,368.46
in general payments reported to CMS, 2019-2025
31 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $775 · 2021: $1,125 · 2022: $1,145 · 2023: $1,054 · 2024: $1,349 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,749.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,046.31 | 2020-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $922.73 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $631.73 | 2020-2024 | Xarelto |
| Amgen INC. | $596.70 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $578.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $492.15 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $354.09 | 2021-2025 | Comet, Accolade Sr, Lux-Dx Insertable Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $337.78 | 2023-2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $312.43 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $222.07 | 2019-2025 | Farxiga |
| Bridgebio Pharma, INC. | $217.68 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $217.02 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.20 | 2019-2025 | Jardiance |
| Medtronic, INC. | $163.83 | 2021-2024 | Hawkone, Onyx Frontier |
| Medtronic Vascular, INC. | $156.82 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $155.59 | 2021-2024 | Sapien 3 Ultra Resilia |
| Acutus Medical, INC. | $134.65 | 2019 | |
| Biotronik INC. | $130.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $120.02 | 2022-2023 | Verquvo |
| Tactile Systems Technology INC | $60.04 | 2024 | Flexitouch Plus, Entre Plus |
| Heartflow, INC. | $50.49 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.29 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $47.48 | 2024 | Arcalyst |
| Cvrx, INC. | $42.60 | 2021-2025 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $24.25 | 2024 | Evkeeza |
| Novo Nordisk INC | $22.65 | 2022 | |
| Impulse Dynamics (USA) INC. | $20.00 | 2022 | |
| Amarin Pharma, INC. | $16.64 | 2019 | |
| Irhythm Technologies, INC. | $16.63 | 2024 | Zio Xt Patch |
| Pacira Pharmaceuticals Incorporated | $15.49 | 2024 | Exparel |
| Ge Healthcare | $14.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stephen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.